HomeOur Strategic Partners

Our Strategic Partners

Stuart Therapeutics regularly attends industry innovation and partnering conferences in both the United States and Europe. Please don’t hesitate to look us up there.

AJU PharmStuart Therapeutics Partners

Stuart Therapeutics is committed to rapidly developing the power and potential of the PolyCol platform technology to deliver transformative, enhanced therapies to address difficult to treat chronic ophthalmic diseases.

For partnering inquiries, or other questions, please contact us below:

Partnering Join Our Team

Eric Schlumpf
President and CEO
[email protected]
Cell: 206.228.2781

Shawn DeLorey
EVP, Program Management and Corporate Development
[email protected]
Cell: 617.513.2701


Stuart Therapeutics has recently completed its Phase 2 clinical trial for its first drug candidate, ST-100 for Dry Eye Disease. The company has also completed extensive in vitro and in vivo research to profile the multiple amino acid sequence variants of the PolyCol platform, including their impact on accelerating tissue healing and reduction of inflammation in other important ophthalmic indications.